Michael S. Weiss serves as the Chief Executive Officer and President of TG Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. With a robust background in the biopharmaceutical industry, Weiss has been instrumental in steering the company towards its goal of bringing innovative therapies to patients in need. Prior to joining TG Therapeutics, he held several leadership positions that honed his strategic vision and operational expertise. Before his tenure at TG Therapeutics, Weiss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, where he successfully led the company through the development and commercialization of Auryxia, a treatment for hyperphosphatemia in patients with chronic kidney disease. Under his leadership, Keryx achieved significant milestones, including FDA approval and a successful commercial launch of Auryxia. Weiss's experience also extends to other notable roles, including positions at Alexion Pharmaceuticals and the law firm of Shearman & Sterling, where he specialized in corporate and securities law. His diverse background in both the legal and biopharmaceutical sectors has equipped him with a unique skill set that he brings to his current role at TG Therapeutics. As CEO and President of TG Therapeutics, Weiss oversees the company's strategic direction, operational execution, and corporate development. His leadership has been pivotal in advancing the company's pipeline, which includes several promising drug candidates in various stages of clinical development. Under his guidance, TG Therapeutics has made significant progress in its mission to address unmet medical needs in hematology and oncology. Weiss's commitment to innovation and patient care continues to drive the company forward, positioning TG Therapeutics as a leader in the development of novel therapies for complex diseases.